Notably, FZD7 can be inhibited by the therapeutic monoclonal antibody Vantictumab (OMP-18R5) which showed potent anti-tumor effects in murine xenograft studies [7] and is currently being tested in clinical trials for various solid cancers. This evidence concerns the gene FZD7 and neoplasm.